# Roche Bets $1.16 Billion on RNAi Weight-Loss Therapy

> Roche secures $1.16 billion RNAi weight-loss drug deal with Rona Therapeutics.
- Title: Roche Bets $1.16 Billion on RNAi Weight-Loss Therapy
- Summary: Roche secures $1.16 billion RNAi weight-loss drug deal with Rona Therapeutics. Roche acquired rights to Rona Therapeutics' ALK7 RNAi weight-loss candidate…
- Keywords: roche, rona therapeutics, alk7, rnai, glp-1, weight-loss, pharmaceuticals, licensing, molecular target, visceral fat, finance, markets
- Source: BigGo Finance — https://finance.biggo.com/news/7a1de7d1-5934-40d7-b274-207d9878a9ec
- Author: BigGo Finance
- Published: 2026-10-14T05:06:09+00:00
- Read time: 1 min
- Topics: roche, rona therapeutics, alk7, rnai, glp-1, weight-loss, pharmaceuticals, licensing, molecular target, visceral fat, finance, markets
## Roche and Rona Therapeutics
Roche entered into a global exclusive licensing agreement with Rona Therapeutics valued at up to $1.16 billion.
## Upfront and Milestone Payments
Rona Therapeutics receives up to $100 million in upfront payments and up to $1.06 billion in development milestone payments.
## ALK7 Target Mechanism
ALK7 acts directly on fat cells to reduce visceral fat while preserving lean body mass.
## Complementary to GLP-1 Therapies
ALK7 therapies could improve weight loss quality and durability compared to GLP-1 drugs that cause muscle loss.
## Rona's Pipeline
Rona Therapeutics has 15 pipeline programs including obesity, hypertension, and cardiomyopathy treatments.
## Competitor Activity
Arrowhead, Alnylam, GSK, and Novo Nordisk are also investing in ALK7 RNAi therapies.
## Roche's Weight-Loss Strategy
Roche acquired enicepatide from Carmot Therapeutics for weight loss and has terminated eight clinical assets in 2026.
## Market Growth Projections
Global weight-loss drug market expected to reach $54 billion by 2030 with 35% annual growth from 2024.
## Clinical Trial Results
Obese patients showed 14.1% visceral fat reduction after eight weeks with single dose of ALK7 RNAi therapy.
## Next Steps for ALK7
Rona Therapeutics' ALK7 candidate must pass clinical trials to become a weight-loss treatment.
## Key takeaway

Roche acquired rights to Rona Therapeutics' ALK7 RNAi weight-loss candidate for up to $1.16 billion, targeting visceral fat reduction without muscle loss.